MARKET

BPMC

BPMC

Blueprint
NASDAQ

Real-time Quotes | Nasdaq Last Sale

74.45
-0.18
-0.24%
After Hours: 74.45 0 0.00% 16:45 08/07 EDT
OPEN
74.28
PREV CLOSE
74.63
HIGH
76.16
LOW
74.00
VOLUME
205.66K
TURNOVER
--
52 WEEK HIGH
93.90
52 WEEK LOW
43.29
MARKET CAP
4.12B
P/E (TTM)
-9.7206
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BPMC stock price target is 97.36 with a high estimate of 110.00 and a low estimate of 76.00.

EPS

BPMC News

More
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on August 1, 2020, the Compensation Committee of Blueprint Medicines' Bo
PR Newswire · 4d ago
Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat
Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.
Zacks · 07/31 15:18
Blueprint Medicines EPS misses by $0.15, beats on revenue
Blueprint Medicines (NASDAQ:BPMC): Q2 GAAP EPS of -$2.28 misses by $0.15. Revenue of $8.34M (+63.2% Y/Y) beats by $1.41M. Press Release
seekingalpha · 07/30 16:05
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -9.62% and 10.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/30 12:35
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29)
Benzinga · 07/30 12:09
Blueprint Medicines Q2 EPS $(2.28) Misses $(2.14) Estimate, Sales $8.34M Beat $6.60M Estimate
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(2.14) by 6.54 percent. This is a 11.76 percent decrease over losses of $(2.04) per share
Benzinga · 07/30 11:45
Blueprint Medicines Reports Second Quarter 2020 Financial Results
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the second quarter ended June 30, 202
PR Newswire · 07/30 11:00
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/30 04:00

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About BPMC

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
More

Webull offers kinds of Blueprint Medicines Corp stock information, including NASDAQ:BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.